US Patent 10953032 Cyclic dinucleotides as anticancer agents
Patent 10953032 was granted and assigned to Bristol-Myers Squibb on March, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+293 characters)
Article
Patent abstract
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Edits on 9 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Brian E. Fink0
Dharmpal S. Dodd0
Yong Zhang0
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
109530320
Date of Patent
March 23, 2021
0Patent Application Number
166424240
Date Filed
August 30, 2018
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 10 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10953032 Cyclic dinucleotides as anticancer agents
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10953032
Date of patent
March 23, 2021
Patent application number
16642424
Date Filed
August 30, 2018
Patent primary examiner
Find more entities like US Patent 10953032 Cyclic dinucleotides as anticancer agents
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
